Pipeline | Decibel Therapeutics

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

DB-020 Cisplatin Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Small molecule

DB-041 Aminoglycoside Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Small molecule

Mechanism: It is thought that aminoglycosides enter cochlear and vestibular hair cells through a specialized mechano-electrical transducer (MET). The pore of the MET channel is large enough to permit the entry of aminoglycosides into the compartment where toxicity occurs. DB-041 is believed to protect against aminoglycoside-induced hair cell death by blocking the entry of aminoglycoside molecules through the MET channel.

Unmet need: Aminoglycoside antibiotics are often the only effective option to treat severe infections despite labeled warnings regarding risk of permanent hearing loss and balance problems. Particularly susceptible populations include those treated for pulmonary exacerbations associated with cystic fibrosis, non-tuberculous mycobacterial infections, and multidrug-resistant tuberculosis.

DB-XX1 Balance Dysfunction

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Gene Therapy

DB-XX2 Monogenic Hearing Loss: Gene 1

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Gene Therapy

DB-XX3 Monogenic Hearing Loss: Gene 2

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Gene Therapy

DB-XX4 Monogenic Hearing Loss: Gene 3

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Gene Therapy

DB-XX5 Tinnitus; Auditory Neuropathy

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

Biologic

Novel target ID Noise, Age,
Tinnitus, Balance

PROGRAM

TARGET ID & VALIDATION

DRUG
DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

PARTNER¹

^{1. Decibel retains worldwide development and commercial rights for all programs

2. Regeneron co-funds the development of collaboration programs and receives tiered royalties based on net sales.}

Learn about our approach